Skip to main content

Advertisement

SpringerLink
Log in

Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Background

To establish a comprehensive diagnostic model for neuromyelitis optica spectrum disorders (NMOSDs) based on laboratory indicators and clinical data.

Methods

A retrospective method was used to query the medical records of patients with NMOSD from January 2019 to December 2021. At the same time, clinical data of other neurological diseases were also collected for comparison. Clinical data of the NMOSD group and non-NMOSD group were analyzed, and the diagnostic model was established based on these data. In addition, the model was evaluated and verified by the receiver operating curve.

Results

A total of 73 patients with NMOSD were included, and the ratio of males to females was 1:3.06. The indicators that showed differences between the NMOSD group and non NMOSD group included neutrophils (P = 0.0438), PT (P = 0.0028), APTT (P < 0.0001), CK (P = 0.002), IBIL (P = 0.0181), DBIL (P < 0.0001), TG (P = 0.0078), TC (P = 0.0117), LDL-C (P = 0.0054), ApoA1 (P = 0.0123), ApoB (P = 0.0217), TPO antibody (P = 0.012), T3 (P = 0.0446), B lymphocyte subsets (P = 0.0437), urine sg (P = 0.0123), urine pH (P = 0.0462), anti-SS-A antibody (P = 0.0036), RO-52 (P = 0.0138), CSF simplex virus antibody I-IGG (P = 0.0103), anti-AQP4 antibody (P < 0.0001), and anti-MOG antibody (P = 0.0036). Logistic regression analysis showed that changes in ocular symptoms, anti-SSA antibody, anti-TPO antibody, B lymphocyte subsets, anti-AQP4 antibody, anti-MOG antibody, TG, LDL, ApoB, and APTT had a significant impact on diagnosis. The AUC of the combined analysis was 0.959. The AUC of the new ROC for AQP4- and MOG- antibody negative NMOSD was 0.862.

Conclusions

A diagnostic model was successfully established, which can play an important role in differential diagnosis of NMOSD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Du Y, Li K, Liu W, Song R, Luo M, He J et al (2022) Recent advances in neuromyelitis optica spectrum disorder: pathogenesis, mechanisms and potential treatments. Curr Pharm Des 28:272–279

    Article  PubMed  Google Scholar 

  2. Cruz RA, Chaudhary S, Guevara M, Meltzer E (2021) Neuromyelitis optica spectrum disorders (NMOSD) and connective tissue disease (CTD): an update for the rheumatologist. Curr Rheumatol Rep 23:33

    Article  PubMed  Google Scholar 

  3. Shahmohammadi S, Doosti R, Shahmohammadi A, Azimi A, Sahraian MA, Fattahi MR et al (2021) Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: a systematic review. Mult Scler Relat Disord 56:103227

    Article  PubMed  Google Scholar 

  4. Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A (2019) Neuromyelitis optica spectrum disorders. Clin Med (Lond) 19:169–176

    Article  PubMed  Google Scholar 

  5. Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D et al (2021) Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 8:e978

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189

    Article  PubMed  PubMed Central  Google Scholar 

  7. Borisow N, Mori M, Kuwabara S, Scheel M, Paul F (2018) Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol 9:888

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15:134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Prasad S, Chen J (2019) What you need to know about AQP4, MOG, and NMOSD. Semin Neurol 39:718–731

    Article  PubMed  Google Scholar 

  10. Denève M, Biotti D, Patsoura S, Ferrier M, Meluchova Z, Mahieu L et al (2019) MRI features of demyelinating disease associated with anti-MOG antibodies in adults. J Neuroradiol 46:312–318

    Article  PubMed  Google Scholar 

  11. Fujihara K (2019) Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol 32:385–394

    Article  PubMed  PubMed Central  Google Scholar 

  12. Holroyd KB, Manzano GS, Levy M (2020) Update on neuromyelitis optica spectrum disorder. Curr Opin Ophthalmol 31:462–468

    Article  PubMed  PubMed Central  Google Scholar 

  13. Levy M, Fujihara K, Palace J (2021) New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 20:60–67

    Article  CAS  PubMed  Google Scholar 

  14. Wang Y, Chang H, Zhang X, Yin L (2021) Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis. Mult Scler Relat Disord 50:102843

    Article  CAS  PubMed  Google Scholar 

  15. Carnero Contentti E, Correale J (2021) Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation 18:208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Pittock SJ, Zekeridou A, Weinshenker BG (2021) Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials. Nat Rev Neurol 17:759–773

    Article  CAS  PubMed  Google Scholar 

  17. Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR et al (2019) Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 15:671–683

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shahrizaila N, Lehmann HC, Kuwabara S (2021) Guillain-Barré syndrome. Lancet 397:1214–1228

    Article  CAS  PubMed  Google Scholar 

  19. Klineova S, Lublin FD (2018) Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med 8:a028928

    Article  PubMed  PubMed Central  Google Scholar 

  20. Athar T, Al Balushi K, Khan SA (2021) Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease. Mol Biol Rep 48:5629–5645

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ferrari C, Sorbi S (2021) The complexity of Alzheimer’s disease: an evolving puzzle. Physiol Rev 101:1047–1081

    Article  CAS  PubMed  Google Scholar 

  22. Bohmwald K, Andrade CA, Gálvez NMS, Mora VP, Muñoz JT, Kalergis AM (2021) The causes and long-term consequences of viral encephalitis. Front Cell Neurosci 15:755875

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M et al (2021) Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry 92:757–768

    Article  PubMed  Google Scholar 

  24. Dutra BG, da Rocha AJ, Nunes RH, Maia ACMJ (2018) Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis. Radiographics 38:169–193

    Article  PubMed  Google Scholar 

  25. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815

    Article  CAS  PubMed  Google Scholar 

  26. Ibis SC, Omaira M, Arnoldo S, Elizabeth A, Sandra M, Carlota CM et al (2021) Epidemiological findings of neuromyelitis optica spectrum disorders in a Venezuelan study. Mult Scler Relat Disord 47:102652

    Article  PubMed  Google Scholar 

  27. Tani J, Liao HT, Hsu HC, Chen LF, Chang TS, Shin-Yi Lin C et al (2020) Immune-mediated axonal dysfunction in seropositive and seronegative primary Sjögren’s syndrome. Ann Clin Transl Neurol 7:819–828

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Li H, Dai Y, Wu AM, Sun X, Lin Y, Lv K et al (2015) Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders. J Neuroimmunol 281:38–43

    Article  CAS  PubMed  Google Scholar 

  29. Habe K, Wada H, Mizutani K, Matsushima Y, Kondo M, Yamanaka K (2021) The clinical significance of a shortened activated partial thromboplastin time in patients with connective tissue disease. Clin Rheumatol 40:4675–4683

    Article  PubMed  Google Scholar 

  30. Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR et al (2021) Abelacimab for prevention of venous thromboembolism. N Engl J Med 385:609–617

    Article  CAS  PubMed  Google Scholar 

  31. Branchford BR, Carpenter SL (2018) The role of inflammation in venous thromboembolism. Front Pediatr 6:142

    Article  PubMed  PubMed Central  Google Scholar 

  32. Wu K, Wen L, Duan R, Li Y, Yao Y, Jing L et al (2019) Triglyceride level is an independent risk factor in first-attacked neuromyelitis optica spectrum disorders patients. Front Neurol 10:1230

    Article  PubMed  PubMed Central  Google Scholar 

  33. Sasabe N, Keyamura Y, Obama T, Inoue N, Masuko Y, Igarashi Y et al (2014) Time course-changes in phosphatidylcholine profile during oxidative modification of low-density lipoprotein. Lipids Health Dis 13:48

    Article  PubMed  PubMed Central  Google Scholar 

  34. Itabe H, Sawada N, Makiyama T, Obama T (2021) Structure and dynamics of oxidized lipoproteins in vivo: roles of high-density lipoprotein. Biomedicines 9:655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Lee JJ, Chi G, Fitzgerald C, Kazmi SHA, Kalayci A, Korjian S et al (2021) Cholesterol efflux capacity and its association with adverse cardiovascular events: a systematic review and meta-analysis. Front Cardiovasc Med 8:774418

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Cencioni MT, Mattoscio M, Magliozzi R, Bar-Or A, Muraro PA (2021) B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat Rev Neurol 17:399–414

    Article  PubMed  Google Scholar 

  37. Etemadifar M, Salari M, Mirmosayyeb O, Serati M, Nikkhah R, Askari M et al (2017) Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci 22:18

    Article  PubMed  PubMed Central  Google Scholar 

  38. Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M et al (2018) MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 25:66–72

    Article  PubMed  Google Scholar 

  39. Chen ZG, Huang J, Fan R, Weng RH, Shinohara RT, Landis JR et al (2020) Urinalysis in patients with neuromyelitis optica spectrum disorder. Eur J Neurol 27:619–625

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Wencan Jiang, Xiaoxuan Yin, and Yufei Wang have contributed equally for this paper.

Authors and Affiliations

  1. Department of Clinical Diagnosis, Laboratory of Beijing Tiantan Hospital and Capital Medical University, No.119, South Fourth Ring West Road, Fengtai District, Beijing, 100070, China

    Wencan Jiang, Xiaoxuan Yin, Yufei Wang, Yaowei Ding, Yu Pan, Guanghui Zheng, Hong Lv, Kelin Chen, Siwen Li, Lijuan Wang, Yijun Shi, Guoge Li & Guojun Zhang

  2. National Engineering Research Centre for Beijing Biochip Technology, Beijing, China

    Wencan Jiang, Xiaoxuan Yin, Yufei Wang, Yaowei Ding, Hong Lv, Kelin Chen, Siwen Li, Lijuan Wang, Yijun Shi, Guoge Li & Guojun Zhang

  3. NMPA Key Laboratory for Quality Control for In Vitro Diagnostic, Beijing, China

    Wencan Jiang, Guanghui Zheng & Guojun Zhang

Authors
  1. Wencan Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoxuan Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yufei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yaowei Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guanghui Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hong Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kelin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Siwen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lijuan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yijun Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Guoge Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Guojun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guojun Zhang.

Ethics declarations

Ethical approval

The study was approved by the Ethical Committee of the Beijing Tiantan Hospital, Capital Medical University (Number: KY2019-095-03).

Informed consent

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Conflict of interest

None

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 58 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, W., Yin, X., Wang, Y. et al. Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data. Neurol Sci 44, 3647–3657 (2023). https://doi.org/10.1007/s10072-023-06853-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-023-06853-2

Keywords

Search

Navigation